BioHarvest Sciences (BHST) is a cannabis biotech company trading on the NASDAQ. The stock is currently priced at $1.46 with a market capitalization of $33.1M and trailing twelve-month revenue of $34.5M. The company reports a gross margin of 59.3%. View SEC filings ↗
Market Cap
$33.1M
Volume
9.6K
Prev Close
$1.54
52W High
$9.25
52W Low
$1.37
P/S Ratio
0.96
Shares Out
22.7M
Revenue
$34.5M
Gross Margin
59.3%
Cash
$23.0M
BHST Price Chart
Trading Data
Valuation Metrics
Financial Highlights
View Full FinancialsBHST Key Takeaways
- BioHarvest Sciences (BHST) trades at $1.46 with a market cap of $33.1M, ranking #36 among 71 cannabis stocks.
- Trailing twelve-month revenue is $34.5M, growing +37.00% year-over-year.
- Gross margin stands at 59.3% — strong margin profile for a cannabis company.
- Balance sheet shows $23.0M cash against $149.0K debt — net cash positive.
- Price-to-Sales ratio of 0.96x — below sector median, potentially undervalued.
- Ranked #3 by market cap in the Biotech sector. Trades on the NASDAQ exchange.
BHST Stock Analysis
BioHarvest Sciences (BHST) is a cannabis biotech company listed on the NASDAQ exchange, headquartered in IL. With a current share price of $1.46 and a market capitalization of $33.1M, BHST ranks #36 out of 71 publicly traded cannabis stocks tracked on Cannabismarketcap.
From a fundamental perspective, BioHarvest Sciences reports trailing twelve-month revenue of $34.5M, representing growth of +37.00% year-over-year. The company maintains a gross margin of 59.3%, which places it among the stronger operators in the cannabis space. At a price-to-sales multiple of 0.96x, the stock appears attractively valued relative to its revenue base.
The company's balance sheet shows $23.0M in cash and equivalents against $149.0K in total debt, resulting in a healthy net cash position of $22.9M. At the current burn rate, estimated cash runway is approximately 38 months. Investors looking for a deeper dive can explore BHST's full financial statements including quarterly breakdowns and balance sheet history.
BHST currently trades within a 52-week range of $1.37 to $9.25. Average daily trading volume stands at 9.6K shares.
Corporate Information
Share Structure
BHST Price History
Investment Snapshot
Programmatic analysis based on available financial data. Not investment advice.
Ranked #36 of 71 by market cap ($33.1M). Sector median: $33.1M.
Net cash: $22.9M ($23.0M cash, $149.0K debt). Gross margin at 59.3%.
Revenue growth at +37.0% YoY. Sector median: +1.6%.
P/S ratio of 0.96x vs sector median of 0.66x. Potentially undervalued.
Cannabis Industry Context
Cannabis Industry Overview
The cannabis biotech sector sits at the intersection of pharmaceutical development and plant-based therapeutics, encompassing companies pursuing FDA-approved cannabinoid medicines, novel drug delivery systems, and clinical-stage research into the endocannabinoid system. Unlike plant-touching operators, cannabis biotechs operate within the established FDA regulatory pathway, conducting preclinical studies and multi-phase clinical trials to demonstrate safety and efficacy for specific therapeutic indications. Epidiolex, a purified CBD formulation approved for rare forms of epilepsy, demonstrated that FDA approval of cannabis-derived pharmaceuticals is achievable and can unlock institutional healthcare investment. The broader pipeline spans indications including chronic pain, PTSD, anxiety, inflammation, and neurological disorders. Biotech investors evaluate these companies using traditional pharmaceutical metrics: pipeline depth, clinical trial stage, probability of regulatory approval, intellectual property protection, and total addressable market for each indication. The sector carries binary risk profiles typical of early-stage drug development but offers significant upside if clinical programs achieve regulatory milestones.
BioHarvest Sciences in the Cannabis Biotech Landscape
BioHarvest Sciences (BHST) currently ranks #3 out of 4 publicly traded cannabis biotech companies by market capitalization, with a market cap of $33.1M. The company reports trailing-twelve-month revenue of $34.5M, placing it above the sector median of $34.5M. The cannabis biotech sector comprises 4 tracked companies, reflecting the focused competitive landscape within this segment of the cannabis industry.
The top companies in the cannabis biotech sector by market capitalization are Jazz Pharmaceuticals (JAZZ) at $14.90B, InnocanPharma (INNPF) at $93.1M, and BioHarvest Sciences (BHST) at $33.1M. BioHarvest Sciences competes within this group for market share, investor attention, and operational scale as the sector continues to mature.
Key Metrics at a Glance
Regulatory & Risk Considerations
All cannabis investors should be aware that federal legalization status in the United States remains uncertain. While cannabis is legal for medical use in the majority of US states and for adult use in a growing number of jurisdictions, it remains classified as a Schedule I controlled substance at the federal level. This creates material legal, financial, and operational risks across the industry. Cannabis biotech companies like BioHarvest Sciences are subject to the rigorous and time-consuming FDA regulatory pathway, which can span 10-15 years and hundreds of millions of dollars from discovery through Phase III clinical trials and New Drug Application (NDA) review. Binary outcomes at each clinical stage create significant volatility, and the majority of drug candidates do not reach commercial approval.
Unique to cannabis biotech is the interaction between the FDA pharmaceutical pathway and the evolving state and federal cannabis regulatory environment. Companies must navigate DEA scheduling requirements for research materials, secure appropriate supply agreements for clinical-grade cannabinoids, and manage intellectual property in a space where natural compounds face patentability challenges. If cannabis is rescheduled or descheduled, the competitive landscape could shift as consumer access to cannabinoid products expands through non-pharmaceutical channels.
Compare BHST With Peers
Related Biotech Stocks
Frequently Asked Questions
What is BioHarvest Sciences's (BHST) stock price today?▼
BioHarvest Sciences (BHST) stock is currently trading at $1.46 per share on the NASDAQ exchange. This represents a daily decline of -5.19% ($0.0800) from the previous closing price of $1.54. Over the past 52 weeks, BHST has traded between a low of $1.37 and a high of $9.25, placing the current price at approximately -84% from its annual high. The stock has a market capitalization of $33.1M, making it a notable cannabis companies tracked by Cannabismarketcap. BioHarvest Sciences operates in the Biotech sector, serving the broader cannabis industry.
What is BioHarvest Sciences's market capitalization?▼
BioHarvest Sciences (BHST) has a current market capitalization of $33.1M, calculated by multiplying its 22.7M shares outstanding by the current stock price of $1.46. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places BioHarvest Sciences among the small-cap cannabis companies tracked on Cannabismarketcap. For context, the enterprise value (market cap plus debt minus cash) stands at $10.2M, which accounts for the company's balance sheet structure. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.
Is BioHarvest Sciences profitable?▼
BioHarvest Sciences (BHST) currently reports a gross margin of 59.3%, which means the company retains 59.3 cents of every revenue dollar after direct costs of goods sold. On trailing twelve month revenue of $34.5M, this translates to an estimated gross profit of approximately $20.5M. Profitability is a critical factor in the cannabis industry, where many companies are still investing heavily in growth and regulatory compliance. Investors should review the full income statement, cash flow trends, and operating expense breakdown on Cannabismarketcap for a complete picture of BioHarvest Sciences's financial health.
What is BioHarvest Sciences's annual revenue?▼
BioHarvest Sciences (BHST) reports trailing twelve month (TTM) revenue of $34.5M, reflecting the total sales generated by the company over the most recent four quarters. Revenue has changed +37.00% year-over-year, indicating growth momentum relative to the prior period. The current price-to-sales ratio is 0.96x, which means investors are paying $0.96 for every $1 of annual revenue — a relatively low valuation in the context of the cannabis sector. Revenue is one of the most closely watched metrics for cannabis companies, as many are still scaling operations in a rapidly evolving regulatory environment. View the full income statement and quarterly revenue breakdown on Cannabismarketcap for detailed trend analysis.
What exchange is BHST listed on?▼
BioHarvest Sciences trades under the ticker symbol BHST on the NASDAQ exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts. The stock sees average daily trading volume of approximately 9.6K shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.
What is BioHarvest Sciences's gross margin?▼
BioHarvest Sciences (BHST) has a gross margin of 59.3%, which represents the percentage of revenue the company retains after paying for the direct cost of goods sold. On trailing twelve month revenue of $34.5M, this translates to an estimated gross profit of approximately $20.5M. Gross margin is a critical profitability indicator in the cannabis industry, where companies face unique cost pressures from regulatory compliance, testing requirements, and the tax burden of IRC Section 280E (which prevents cannabis companies from deducting standard business expenses). A strong gross margin like BioHarvest Sciences's suggests the company has pricing power and operational efficiency relative to peers.
What is BHST's 52-week trading range?▼
BioHarvest Sciences (BHST) has traded between a 52-week low of $1.37 and a 52-week high of $9.25, with the current price of $1.46 sitting approximately -84% from the annual high. This range represents a spread of $7.88 (575% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.
What is BioHarvest Sciences's cash position and debt level?▼
BioHarvest Sciences (BHST) holds $23.0M in cash and equivalents on its balance sheet, set against $149.0K in total debt. This gives the company a net cash position of $22.9M. At the current rate of cash usage, the company has an estimated cash runway of approximately 38 months before needing additional financing, which could come from operations, debt, or equity issuance. Balance sheet strength is especially important in the cannabis industry, where companies often face limited access to traditional banking and capital markets. Investors should track these metrics over time on Cannabismarketcap to identify trends in cash consumption and debt management.
How many shares outstanding does BioHarvest Sciences have?▼
BioHarvest Sciences (BHST) currently has 22.7M shares outstanding, which when multiplied by the current stock price of $1.46 gives the company its market capitalization of $33.1M. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.
Embed BHST Widget
Add the BHST price widget to your website or blog:
<iframe src="https://cannabismarketcap.io/embed/bhst" width="320" height="180" frameborder="0" style="border-radius:8px;border:1px solid #415a77"></iframe>Data updates every 2 minutes. Free for non-commercial use.
Disclaimer
The information on this page is provided for informational purposes only and does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Cannabismarketcap is not a registered broker-dealer or investment advisor. All data, including stock prices, market capitalizations, financial metrics, and analysis for BioHarvest Sciences (BHST), is provided “as is” without warranty of any kind. Past performance does not guarantee future results. Cannabis stocks are highly volatile and carry significant risk, including the potential for total loss of investment. Marijuana remains illegal under federal law in the United States. Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions. Data may be delayed or inaccurate. See our terms of service and privacy policy for more information.